NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT03464734 2022-11-30
Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03051373 2021-08-09
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Chinese PLA General Hospital
Phase 2 Completed
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00467051 2018-08-29
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT02718742 2016-04-18
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer
Mayo Clinic
Phase 2 Withdrawn
NCT00005831 2013-01-14
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed